2 Burlington Woods Drive
Suite 100
Burlington, MA 01803
United States
781 552 4452
https://www.bonebiologics.com
Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 2
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Jeffrey Frelick | CEO & President | 325k | S.O. | 1966 |
Ms. Deina H. Walsh | Chief Financial Officer | 212,5k | S.O. | 1964 |
Dr. Shun'ichi Kuroda | Co-Founder & Member of Scientific Advisory Board | S.O. | S.O. | S.O. |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
L’ISS Governance QualityScore de Bone Biologics Corporation en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..